Understanding how a specific brain transporter works and how it can be inhibited
Transport Cycle and Inhibition of Human Na+-dicarboxylate Cotransporter NaDC3
This study is looking at a special transporter in the brain that helps move important molecules, and it's hoping to find ways to improve treatments for conditions like Canavan disease, which can be affected when this transporter doesn't work properly.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11004704 on NIH RePORTER |
What this research studies
This research investigates the Na+-driven dicarboxylate transporter NaDC3, which is crucial for transporting important molecules in the brain and other tissues. The project aims to explore how this transporter works, including its structure and the mechanisms by which it can be inhibited. By studying the transport cycle and the conformational changes of NaDC3, researchers hope to uncover insights that could lead to new treatments for conditions like Canavan disease, which is linked to dysfunction in this transporter. Patients may benefit from potential therapies that target this transporter to alleviate symptoms of related disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Canavan disease or other central nervous system disorders related to NaDC3 dysfunction.
Not a fit: Patients with conditions unrelated to NaDC3 or those who do not have central nervous system disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with Canavan disease and other related conditions.
How similar studies have performed: Other research has shown promise in targeting similar transport mechanisms, indicating potential for success in this area.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wang, Daneng — New York University School of Medicine
- Study coordinator: Wang, Daneng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.